Most importantly, our findings suggest the potential usefulness of the circulating levels of IgG, CD38 and GDF15 to assist AAA management in conjunction with aneurysm diameter and/or PWS during the follow-up of these patients. The gene discussed is CD38; the disease is aneurysm.